Vertex Pharmaceuticals Inc (VRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $136.35B
Last updated: Nov 17, 2026 at 4:39 PM ET
Vertex Pharmaceuticals Inc (VRTX) Statistics
Vertex Pharmaceuticals (VRTX) has a market cap of $136.35B and an enterprise value of $135.87B. It kept 30.70% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 0.35% below the market cap, as cash exceeds debt.
| Market Cap | $136.35B |
|---|---|
| Enterprise Value | $135.87B |
| Latest price (Nov 17, 2026) | $534.20 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 10.5x and 6.5x. Its year-end P/E ranged from 16.9x to 87.7x from 2016 to 2025.
| P/E Ratio | 29.8x |
|---|---|
| Forward P/E | 28.7x |
| P/S Ratio | 10.5x |
| Forward P/S | 10.3x |
| P/B Ratio | 6.5x |
| P/TBV Ratio | 13.6x |
| P/FCF Ratio | 42.3x |
| P/OCF Ratio | 36.9x |
| PEG Ratio | 2.2 |
Enterprise Valuation
Counting debt and cash, the company is valued at 29.6x EBITDA and 42.1x free cash flow.
| EV / Earnings | 34.2x |
|---|---|
| EV / Sales | 10.5x |
| EV / EBITDA | 29.6x |
| EV / FCF | 42.1x |
Price Statistics
The stock is up 22.20% over 52 weeks and trades 2.28% above its 50-day average.
| Beta (1Y) | 0.43 |
|---|---|
| 52-Week Change | +22.20% |
| 1-Month Change | +6.42% |
| 3-Month Change | -3.24% |
| 6-Month Change | +23.00% |
| 5-Year Change | +202.21% |
| 10-Year Change | +636.73% |
| Total Return (1Y) | +22.20% |
| Total Return (3Y CAGR) | +15.08% |
| Total Return (5Y CAGR) | +23.59% |
| Return vs SPY (1Y) | +11.10% |
| Max Drawdown (1Y) | -15.21% |
| Max Drawdown (3Y) | -29.07% |
| Sharpe Ratio (1Y) | 0.70 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $522.31 |
| 200-Day Average | $483.99 |
| 52-Week Range | $412.27 to $568.67 |
| RSI (14 Days) | 50.4 |
| Average Volume (20 Days) | 1.56M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.34x current liabilities, and total debt is 0.22x shareholder equity.
| Current Ratio | 2.34x |
|---|---|
| Quick Ratio | 1.89x |
| Debt / Equity | 0.22x |
| Debt / EBITDA | 0.99x |
| Debt / FCF | 1.40x |
| Interest Coverage | 313.20x |
Returns and Efficiency
Return on invested capital is 14.22% over the last 12 months, against a 5-year average of 19.00%.
| Return on Equity (ROE) | 19.02% |
|---|---|
| Return on Assets (ROA) | 12.15% |
| Return on Invested Capital (ROIC) | 14.22% |
| ROE (5Y Average) | 17.11% |
| ROA (5Y Average) | 12.94% |
| ROIC (5Y Average) | 19.00% |
| Asset Turnover | 0.45x |
| Inventory Turnover | 0.93x |
| Receivables Turnover | 5.83x |
| Cash Conversion Cycle | 365 days |
Taxes
Income tax took 16.46% of pretax income over the last 12 months.
| Income Tax (TTM) | $783.20M |
|---|---|
| Effective Tax Rate | 16.46% |
Scores
VRTX has an Altman Z-Score of 8.64, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 8.64 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $12.95B over the last 12 months is up 10.48% from the 12 months before.
| Revenue | $12.95B |
|---|---|
| Revenue Growth (YoY) | +10.48% |
| Gross Profit | $11.08B |
| Operating Income | $4.30B |
| Pretax Income | $4.76B |
| Net Income | $3.98B |
| Reported EPS (TTM) | $17.91 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 63.87% of the $32.74B in total assets.
| Cash and Equivalents | $4.98B |
|---|---|
| Total Debt | $4.50B |
| Net Cash | $482.70M |
| Net Cash Per Share | $1.90 |
| Working Capital | $6.69B |
| Shareholder Equity | $20.91B |
| Book Value Per Share | $82.47 |
| Tangible Book Value | $9.97B |
| Tangible Book Per Share | $39.31 |
| Total Assets | $32.74B |
| Total Liabilities | $11.83B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $492.30M of capital spending, operating cash flow left $3.20B of free cash flow.
| Operating Cash Flow | $3.69B |
|---|---|
| Capital Expenditures | $492.30M |
| Free Cash Flow | $3.20B |
| FCF Per Share | $12.63 |
| Depreciation and Amortization | $237.30M |
| Share Repurchases | $1.06B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 33.23%, against a 5-year average of 31.29%.
| Gross Margin | 85.53% |
|---|---|
| Operating Margin | 33.23% |
| Pretax Margin | 36.75% |
| Net Margin | 30.70% |
| FCF Margin | 24.73% |
| Gross Margin (5Y Average) | 87.11% |
| Operating Margin (5Y Average) | 31.29% |
| Net Margin (5Y Average) | 26.57% |
Growth
Revenue grew 10.35% a year over 3 years, and EPS 7.33% a year.
| Revenue Growth (3Y CAGR) | +10.35% |
|---|---|
| Revenue Growth (5Y CAGR) | +14.10% |
| EPS Growth (3Y CAGR) | +7.33% |
| EPS Growth (5Y CAGR) | +12.27% |
| FCF Growth (3Y CAGR) | -6.64% |
| FCF Growth (5Y CAGR) | +1.30% |
| Operating Income Growth (3Y CAGR) | -1.05% |
| Book Value Per Share Growth (2Y CAGR) | +4.00% |
| Tangible Book Per Share Growth (2Y CAGR) | +5.66% |
Dividends and Yields
VRTX does not pay a dividend. Its free cash flow yield is 2.36%.
| Earnings Yield | 3.36% |
|---|---|
| FCF Yield | 2.36% |
| Buyback Yield | 0.67% |
| Shareholder Yield | 0.67% |
Stock Splits
The last split was a 2-for-1 forward split on Aug 24, 2000.
| Last Split Date | Aug 24, 2000 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 5 similar companies, VRTX has the 4th highest P/E.
P/E RatioPeer median 33.2x
P/S RatioPeer median 15.9x
ROICPeer median -28.89%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +15.86%
| P/E Ratio | 29.8x vs 33.2x median |
|---|---|
| P/S Ratio | 10.5x vs 15.9x median |
| ROIC | 14.22% vs -28.89% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +10.48% vs +15.86% median |
Analyst Forecast
Consensus estimates put revenue growth at 10.50% and EPS growth at 4.01% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +10.50% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +4.01% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VRTX
What is VRTX's market cap?
Vertex Pharmaceuticals has a market cap of $136.35B. Its enterprise value, which adds debt and subtracts cash, is $135.87B.
What is VRTX's P/E ratio?
Vertex Pharmaceuticals has a trailing P/E ratio of 29.8x and a forward P/E of 28.7x.
How many shares of VRTX are outstanding?
Vertex Pharmaceuticals has 253.50M shares outstanding. The count is down 0.82% from a year earlier.
Does VRTX pay a dividend?
No. Vertex Pharmaceuticals does not pay a dividend.
How much debt does VRTX have?
Vertex Pharmaceuticals has $4.50B of total debt and $4.98B of cash and equivalents, a net cash position of $482.70M.
VRTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors